Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: A randomized double-blind study

Chest

Volumn 125, Issue 4, 2004, Pages 1198-1204

  Nanas, John N ^a,b   Tsagalou, Eleftheria P ^a   Kanakakis, John ^a   Nanas, Serafim N ^a   Terrovitis, John V ^a   Moon, Thomas ^a   Anastasiou Nana, Maria I ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Heart failure; Inotropic agents; Survival

Indexed keywords

AMIODARONE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; FEMALE; HOSPITAL PATIENT; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 7944227178     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.4.1198     Document Type: Article

References (37)

1. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001; 22:1318-1327
2. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44-54
3. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133:703-712
4. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336:1-6
5. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475
6. Narahara KA. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial; The Western Enoximone Study Group. Am Heart J 1991; 121:1471-1479
7. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329:149-155
8. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533
9. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142:393-401
10. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31:1336-1340
11. Nanas JN, Kontoyannis DA, Alexopoulos GP, et al. Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest 2001; 119:1173-1178
12. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle; the CASCADE Investigators. Am J Cardiol 1993; 72:70F-74F
13. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983; 106:788-797
14. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:493-498
15. Collins JA, Skidmore MA, Melvin DB, et al. Home intravenous dobutamine therapy in patients awaiting heart transplantation. J Heart Transplant 1990; 9:205-208
16. Gibelin P, Sbirrazzuoli V, Drici M, et al. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. Cardiovasc Drugs Ther 1990; 4:1105-1112
17. Miller LW. Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results. J Heart Lung Transplant 1991; 10:482-487
18. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112:787-791
19. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986; 74:II-38
20. Tisdale JE, Patel R, Webb CR, et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38:167-180
21. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long term use of a left ventricular assist device for end-stage heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) study group. N Engl J Med 2001; 345:1435-1443
22. Massie BM, Fisher SG, Deedwania PC, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93:2128-2134
23. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658
24. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83:778-786
25. Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 2000; 19:S49-S57
26. Liang CS, Sherman LG, Doherty JU, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 1984; 69:113-119
27. John RM, Taggart PI, Sutton PM, et al. Direct effect of dobutamine on action potential duration in ischemic compared with normal areas in the human ventricle. J Am Coll Cardiol 1992; 20:896-903
28. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350:1417-1424
29. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341:871-878
30. Haikerwal D, Dart AM, Little PJ, et al. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther 1999; 288:834-837
31. Unverferth DV, Magorien RD, Lewis RP, et al. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100:622-630
32. Adamopoulos S, Piepoli M, Qiang F, et al. Effects of pulsed β-stimulant therapy on β-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 1995; 345:344-349
33. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998; 41:207-224
34. Unverferth DV, Magorien RD, Altschuld R, et al. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1983; 106:29-34
35. Binkley PF, Van Fossen DB, Nunziata E, et al. Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol 1990; 15:1127-1135
36. Drvota V, Haggblad J, Blange I, et al. The effect of amiodarone on the b-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction. Biochem Biophys Res Commun 1999; 225:515-520
37. 3 on beta adrenergic receptor in rat heart. Horm Metab Res 1990; 22:85-89